Amble Health vs Henry Meds vs Yucca Health (2026)

On tirzepatide, the order is Yucca Health↗ ($258) → Amble Health ($300) → Henry Meds↗ ($349) — gaps of $42 and then $49 a month, a $1,092 spread across a year between first and last. All-in figures, 10 mg basis, captured 2026-08-09.

Updated 2026-08-10 · figures captured 2026-08-09 · how we verify

§ Each record, condensed

The three records, one screen

Yucca Health: the record, condensed

On tirzepatide, the number that matters at Yucca Health is $258 a month all-in — the figure at the 10 mg maintenance basis this whole site ranks on. The price is dose-flat: the standard titration ladder (2.5 → 5 → 7.5 → 10 mg (12.5 and 15 mg available)) is financially invisible here, because the top rung bills exactly what the bottom rung billed. That converts the advertised number from a floor into a ceiling — the strongest single structural feature a program in this category can have.

The absence worth noticing: no mandatory membership. Across this index memberships run $25–$145 a month and hide outside headline prices; here the headline is the bill.

To place the number: #2 of 17 verified programs, with the floor $43/month below at NexLife↗ ($215); the approved-product yardstick (Zepbound (LillyDirect↗)) sits at $449, so the compounded case here is worth $191 a month. A year at this figure: $3,096 monthly-billed.

On semaglutide, the number that matters at Yucca Health is $146 a month all-in — the figure at the 2.4 mg maintenance basis this whole site ranks on. Because pricing is flat across the ladder (0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg), a dose increase at Yucca Health is a clinical event and not a billing one. Whatever your prescriber decides, the invoice does not move, which makes this one of the few programs whose headline figure you can actually plan a year around.

The absence worth noticing: no mandatory membership. Across this index memberships run $25–$145 a month and hide outside headline prices; here the headline is the bill.

Context for that figure: it ranks #2 of 20 in the verified semaglutide index — $13/month above the floor (Oak Longevity, $133) — and sits $203 under the brand benchmark (Wegovy (NovoCare↗), $349 at maintenance). Annualized, a monthly-billed year here runs $1,752.

Operationally at Yucca Health: shipping included; commitment 6-month term; cancellation 6-month term applies; pharmacy not publicly named — ask in writing before paying; states: not published; evidence source-verified, captured 2026-08-05. The full record with source and archive links: the Yucca Health page · visit Yucca Health ↗

Amble Health: the record, condensed

Start with the load-bearing figure: $300 a month, all-in, is what Amble Health charges for tirzepatide at the 10 mg basis. It is a flat structure: 2.5 → 5 → 7.5 → 10 mg (12.5 and 15 mg available) all bill identically. In a market where most low advertised prices quietly belong to the starter dose, a flat figure is the difference between a quote and a teaser.

The absence worth noticing: no mandatory membership. Across this index memberships run $25–$145 a month and hide outside headline prices; here the headline is the bill.

To place the number: #9 of 17 verified programs, with the floor $85/month below at NexLife ($215); the approved-product yardstick (Zepbound (LillyDirect)) sits at $449, so the compounded case here is worth $149 a month. A year at this figure: $3,600 monthly-billed.

Operationally at Amble Health: shipping unknown; commitment unknown; cancellation not published; pharmacy not publicly named — ask in writing before paying; states: not published; evidence third-party reported, captured 2026-08-05. The full record with source and archive links: the Amble Health page

Henry Meds: the record, condensed

Start with the load-bearing figure: $349 a month, all-in, is what Henry Meds charges for tirzepatide at the 10 mg basis. It is a flat structure: 2.5 → 5 → 7.5 → 10 mg (12.5 and 15 mg available) all bill identically. In a market where most low advertised prices quietly belong to the starter dose, a flat figure is the difference between a quote and a teaser.

Nothing recurs on top: no membership, no platform fee, no “provider access” line. The $349 is the whole subscription, which makes Henry Meds unusually easy to compare and unusually easy to leave.

To place the number: #10 of 17 verified programs, with the floor $134/month below at NexLife ($215); the approved-product yardstick (Zepbound (LillyDirect)) sits at $449, so the compounded case here is worth $100 a month. A year at this figure: $4,188 monthly-billed.

Henry Meds’s semaglutide program bills $179 a month once every mandatory fee is counted, measured at the 2.4 mg maintenance basis. It is a flat structure: 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg all bill identically. In a market where most low advertised prices quietly belong to the starter dose, a flat figure is the difference between a quote and a teaser.

The absence worth noticing: no mandatory membership. Across this index memberships run $25–$145 a month and hide outside headline prices; here the headline is the bill.

Context for that figure: it ranks #9 of 20 in the verified semaglutide index — $46/month above the floor (Oak Longevity, $133) — and sits $170 under the brand benchmark (Wegovy (NovoCare), $349 at maintenance). Annualized, a monthly-billed year here runs $2,148.

Operationally at Henry Meds: shipping included; commitment none month-to-month; cancellation check terms before prepaying; pharmacy not publicly named — ask in writing before paying; states: most states; evidence third-party reported, captured 2026-08-05. The full record with source and archive links: the Henry Meds page · visit Henry Meds ↗

§ The three-way read

Prices, gaps, and what sits inside them

Yucca Health holds the low ground at $258 — dose-flat, so that figure is a ceiling with no membership attached. Amble Health follows at $300 (+$42/mo, $504/yr). Henry Meds tops the trio at $349 (+$91/mo over the leader, $1,092/yr) — note its record’s watch-out below.

The semaglutide picture reshuffles nothing: Yucca Health $146 → Henry Meds $179 — a reminder that molecule choice and provider choice are separate decisions, priced separately in the semaglutide index.

§ Category winners among the three

Who wins what

Cheapest month-to-month: Yucca Health ($258); cheapest 12-month path: Yucca Health ($3,096); cheapest semaglutide of the three: Yucca Health ($146).

Every winner above is a computation, not a placement; the pairwise pages carry the full duels: Yucca Health vs Amble Health (record · record) · Yucca Health vs Henry Meds · Amble Health vs Henry Meds (record · record).

§ Structure, three ways

Everything besides the three prices

Memberships: Yucca Health none; Amble Health none; Henry Meds none. Structures: Yucca Health dose-flat; Amble Health dose-flat; Henry Meds dose-flat. Pharmacies: Yucca Health not named; Amble Health not named; Henry Meds not named. States: Yucca Health — not published; Amble Health — not published; Henry Meds — most states. Exit terms: Yucca Health — 6-month term applies; Amble Health — not published; Henry Meds — check terms before prepaying.

The census reading: where all three match on an axis, that axis cannot break the tie and the price column rules; where they split — a membership here, an unnamed pharmacy there — the split is usually worth more than a small price gap, because structure is what you live with after month one. Evidence for all three: Yucca Health source-verified (2026-08-05); Amble Health third-party reported (2026-08-05); Henry Meds third-party reported (2026-08-05).

The trio on semaglutide, across time

3 mo: Yucca Health $438 vs Henry Meds $537 6 mo: Yucca Health $876 vs Henry Meds $1,074 12 mo: Yucca Health $1,752 vs Henry Meds $2,148 — monthly-billed totals; prepaid paths where published appear on each provider page.

§ Twelve and twenty-four months

The trio, annualized

Yucca Health: $3,096/yr monthly-billed; Amble Health: $3,600/yr monthly-billed; Henry Meds: $4,188/yr monthly-billed. Across two years at monthly billing the first-to-last spread widens to $2,184 — the horizon at which structure (prepaid ladders, flat pricing, membership drag) matters more than the sticker.

The elimination read

A three-way choice is really two eliminations, so run them in order. Eliminate Henry Meds first unless it names its edge: at $349 it carries a $91/month premium over the floor of this trio — $1,092 a year, about 4.2 extra months of therapy at Yucca Health’s rate — and a premium that size must point at a specific line in its record (its particular program design) or it is decoration. Then interrogate Amble Health’s middle ground: nothing structural — its case is purely situational; if that specific thing is on your personal ledger, the $42/month over the floor can be rational — if not, the middle is where budgets go to leak. What survives is Yucca Health at $258, which wins by default rather than by argument — exactly how a price index should crown things — subject to the two checks no ranking can run for you: your state at intake, and your prescriber on the medication itself.

The same trio on best published rate: Yucca Health $258 → Amble Health $300 → Henry Meds $349 — all three price month-to-month only at capture. Short-horizon totals, monthly-billed: 3 months — Yucca Health $774, Amble Health $900, Henry Meds $1,047; 6 months — Yucca Health $1,548, Amble Health $1,800, Henry Meds $2,094. 0 of the three publish a prepaid path below their own monthly billing; the twelve- and twenty-four-month table below carries those, labeled.

The record-quality read, scored on the five checkable disclosures this index tracks (maintenance price, named pharmacy, published states, published cancellation terms, source-verified capture): Yucca Health 4/5, Amble Health 3/5, Henry Meds 3/5. Yucca Health discloses the most and Amble Health the least, and in this market disclosure predicts disclosure — the axis where a program goes quiet is reliably where its checkout surprises live. The three match on every disclosure axis, which is rare and worth noting in their favor collectively. Scores recompute from the public records like everything else here.

Read as a decision: start from Yucca Health and make the other two argue upward. Amble Health’s case is its structure; Henry Meds’s case must be worth $1,092 a year in named features — the honest unit being months of medication (4.2 of them at the floor rate). The pairwise pages above hold each argument in full, and the calculator holds your version of it.